← Browse by Condition
Medical Condition
multiple myeloma
Total Trials
44
Recruiting Now
44
Trial Phases
Phase 2, Phase 1, Phase 2, Phase 1
NCT05001087
Recruiting
A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)
Enrollment
1,900 pts
Location
Italy
Sponsor
Fondazione EMN Italy Onlus
NCT05636787 Phase 2
Recruiting
Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients
Enrollment
120 pts
Location
Switzerland
Sponsor
Insel Gruppe AG, University Ho...
NCT05031897 Phase 2
Recruiting
Two Step Haplo With Radiation Conditioning
Enrollment
63 pts
Location
United States
Sponsor
Thomas Jefferson University
NCT07448935
Recruiting
One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS
Enrollment
100 pts
Location
Italy
Sponsor
Fondazione IRCCS Policlinico S...
NCT03761108 Phase 1, Phase 2
Recruiting
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Enrollment
387 pts
Location
United States, Belgi...
Sponsor
Regeneron Pharmaceuticals
NCT06953960 Phase 1, Phase 2
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Enrollment
130 pts
Location
United States, Austr...
Sponsor
AbbVie
NCT06616389 Phase 1, Phase 2
Recruiting
Study of ODX (OsteoDex) in Multiple Myeloma
Enrollment
12 pts
Location
Sweden
Sponsor
DexTech Medical AB
NCT03689595
Recruiting
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Enrollment
30,000 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
NCT06644118 Phase 1
Recruiting
A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment
58 pts
Location
China
Sponsor
Zhejiang University
NCT05336383 Phase 2
Recruiting
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
Enrollment
30 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT04558931 Phase 2
Recruiting
Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma
Enrollment
62 pts
Location
Sweden
Sponsor
Karolinska Institutet
NCT06933277
Recruiting
Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients
Enrollment
159 pts
Location
Italy
Sponsor
Gruppo Italiano Malattie EMato...
NCT06759181 Phase 1, Phase 2
Recruiting
Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
Enrollment
20 pts
Location
China
Sponsor
Xuzhou Medical University
NCT06997081 Phase 2
Recruiting
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma
Enrollment
104 pts
Location
United States
Sponsor
University of Miami
NCT04662294 EARLY_Phase 1
Recruiting
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
Enrollment
108 pts
Location
China
Sponsor
Zhejiang University
NCT06572605 Phase 1, Phase 2
Recruiting
External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease
Enrollment
20 pts
Location
United States
Sponsor
City of Hope Medical Center
NCT05243797 Phase 3
Recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Enrollment
1,594 pts
Location
United States, Argen...
Sponsor
European Myeloma Network B.V.
NCT07180992
Recruiting
Quantitative and Qualitative Monocytes Analysis and Their Impact on CART Cells Reponse in Multiple Myeloma
Enrollment
25 pts
Location
France
Sponsor
Centre Hospitalier Universitai...
NCT06348108 Phase 1
Recruiting
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Enrollment
32 pts
Location
United States
Sponsor
Alfred Chung, MD
NCT06895291
Recruiting
Whole Body MRI in Oncology
Enrollment
1,000 pts
Location
Italy
Sponsor
Istituto Romagnolo per lo Stud...
NCT05618041
Recruiting
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
Enrollment
50 pts
Location
China
Sponsor
Hebei Senlang Biotechnology In...
NCT06711705 Phase 2
Recruiting
Elranatamab in Relapsed/Refractory Multiple Myeloma
Enrollment
33 pts
Location
United States
Sponsor
University of California, San ...
NCT01676805
Recruiting
Tissue Collection for Studies of Lymph Cancer
Enrollment
1,295 pts
Location
United States, Jamai...
Sponsor
National Cancer Institute (NCI...
NCT05722405 Phase 4
Recruiting
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
Enrollment
100 pts
Location
China
Sponsor
Second Affiliated Hospital, Sc...
NCT06138275 Phase 2
Recruiting
Elranatamab in R/R Multiple Myeloma
Enrollment
32 pts
Location
United States
Sponsor
Massachusetts General Hospital
NCT07258511 Phase 3
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Enrollment
400 pts
Location
United States, Austr...
Sponsor
Janssen Research & Development...
NCT05521802 Phase 1, Phase 2
Recruiting
A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment
92 pts
Location
China
Sponsor
Shanghai AbelZeta Ltd.
NCT06140966 Phase 2
Recruiting
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Enrollment
54 pts
Location
China
Sponsor
Union Hospital, Tongji Medical...
NCT06483100 Phase 2
Recruiting
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Enrollment
65 pts
Location
United States
Sponsor
Washington University School o...
NCT06066346 Phase 2
Recruiting
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Enrollment
17 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
NCT05190653
Recruiting
Early Integration of Palliative and Supportive Care in Cellular Therapy
Enrollment
152 pts
Location
Canada
Sponsor
Alberta Health Services, Calga...
NCT06152575 Phase 3
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Enrollment
492 pts
Location
United States, Argen...
Sponsor
Pfizer
NCT05956457
Recruiting
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
Enrollment
100 pts
Location
United States
Sponsor
Pack Health
NCT05968417
Recruiting
Myeloma Novel Drug Discovery Ver 1.2
Enrollment
250 pts
Location
United Kingdom
Sponsor
Institute of Cancer Research, ...
NCT05768178 Phase 2, Phase 3
Recruiting
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Enrollment
30 pts
Location
United Kingdom
Sponsor
Cancer Research UK
NCT07248176
Recruiting
Universal CAR-T Cell Therapy for MM
Enrollment
6 pts
Location
China
Sponsor
Bioray Laboratories
NCT05695508 Phase 2
Recruiting
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
Enrollment
160 pts
Location
Germany
Sponsor
University of Heidelberg Medic...
NCT06464991 Phase 3
Recruiting
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Enrollment
240 pts
Location
China
Sponsor
Nanjing IASO Biotechnology Co....
NCT07105059 Phase 1
Recruiting
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
Enrollment
18 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
NCT06588413 Phase 3
Recruiting
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
Enrollment
172 pts
Location
United States
Sponsor
Augusta University
NCT06340646
Recruiting
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
Enrollment
990 pts
Location
United States
Sponsor
Washington University School o...
NCT06463717
Recruiting
Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
Enrollment
210 pts
Location
China
Sponsor
First Affiliated Hospital of Z...
NCT06768489 Phase 1
Recruiting
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Enrollment
140 pts
Location
Australia, Israel, N...
Sponsor
Janssen Research & Development...
NCT06142396 EARLY_Phase 1
Recruiting
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
Enrollment
30 pts
Location
United States
Sponsor
Augusta University